Drugs / HH30134
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04746612 | Apr 2021 → Mar 2023 | cancer | Haihe Biopharma Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH30134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04746612 ↗ |
| Route | Oral | “HH30134 administered orally on a continuous once daily(QD)” NCT04746612 ↗ |